Levomilnacipran Hydrochloride Capsule, Extended Release
NDC Package 0456-2221-00

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings
Table of Contents
    1. Package Information
    2. Frequently Asked Questions

Package Information

This product is an UNFINISHED DRUG part of the official NDC directory. Unfinished drugs include products like active ingredients some of which are used in bulk for further processing or compounding. The FDA requires a list of these drugs manufactured in a U.S. commercial distribution facility.

Levomilnacipran Hydrochloride capsules is a drug for further processing. This formulation utilizes a capsule, extended release delivery system. Marketed by Allergan, Inc., this product is identified by NDC 0456-2221.

Identification & Billing

NDC Package Code
0456-2221-00
Package Description
1 BAG in 1 DRUM / 67000 CAPSULE, EXTENDED RELEASE in 1 BAG
Product Code
0456-2221
11-Digit Billing Format
00456222100

Clinical Specifications

Proprietary Name
Levomilnacipran Hydrochloride
Non-Proprietary Name
Levomilnacipran Hydrochloride
Substance Name
Levomilnacipran Hydrochloride
Dosage Form
Capsule, Extended Release - A solid dosage form in which the drug is enclosed within either a hard or soft soluble container made from a suitable form of gelatin, and which releases a drug (or drugs) in such a manner to allow a reduction in dosing frequency as compared to that drug (or drugs) presented as a conventional dosage form.
Active Ingredient(s)
LEVOMILNACIPRAN HYDROCHLORIDE 20 mg/1

Regulatory & Marketing

Labeler Name
Allergan, Inc.
Product Type
Drug For Further Processing
Marketing Category
DRUG FOR FURTHER PROCESSING - A drug (other than the bulk ingredient API) that is in an interim stage of manufacture, processing, preparation, or packaging, and not ready for human or animal use.
Start Marketing Date
01-22-2008
Listing Expiration
12-31-2026
Exclude Flag
N
Unfinished Product
Yes
Sample Package
N/A

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 0456-2221-00 identifies a specific commercial package of 1 bag in 1 drum / 67000 capsule, extended release in 1 bag of Levomilnacipran Hydrochloride (UNFINISHED drug), drug for further processing labeled by Allergan, Inc.. This capsule, extended release is formulated for use and contains levomilnacipran hydrochloride as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Allergan, Inc. on January 22, 2008. The current certification is valid through December 31, 2026.

How is this Allergan, Inc. product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 00456222100. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (4-4-2)
0456-2221-00
11-Digit CMS (5-4-2)
00456-2221-00

Note: The zero is added to the Labeler segment to maintain the 5-4-2 structure.